about
Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathwayThe Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer CellsRole of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cellsRelationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinomaUpdate on inflammatory breast cancerIdentification of a three-gene expression signature of poor-prognosis breast carcinomaThe clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variantsNF-kappa B genes have a major role in inflammatory breast cancerAn entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predispositionIsolation of mineralizing Nestin+ Nkx6.1+ vascular muscular cells from the adult human spinal cord.microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.PIK3R1 underexpression is an independent prognostic marker in breast cancer.Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues.Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy.A Molecular Predictor Reassesses Classification of Human Grade II/III GliomasGenetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumorsDescription and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases.MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?The growing family of hereditary renal cell carcinoma.Identification of new candidate therapeutic target genes in triple-negative breast cancerPIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis.The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.
P50
Q21135589-011AF9CA-DC0C-486F-B1A3-4B03C724FE8BQ24319064-C5BD8B8C-6C9E-4D30-A47A-F4A9C01B5D26Q24642091-BAD6AC36-E56B-4862-8627-01D51AC65DBAQ24795015-B4E12DA0-782D-4437-8993-E9F1913A1658Q24797853-18E61A7F-8CD5-41C6-8C68-DC5FD4DB56FEQ24802692-C2FB069E-1917-4203-A606-38F4F4B15CABQ27824864-0436B423-43E6-4785-A6B7-93BA1F44C2D1Q28264559-89215111-402C-4441-B995-F517861ED751Q33318125-3BA21880-6C28-4FAB-82E6-DFD2FCECE447Q34027876-D2686BAF-EF07-4C4C-AE95-77175A06ADA2Q34045199-F7B5F6E4-123D-4C1B-81F6-4A3E22F6F3ADQ34312916-585D83A7-91F3-4E0B-A5B2-29B840E5C3E2Q34478129-FA241381-66E5-47AA-B0ED-8AAB4680AEC1Q34563697-23D974A6-1F2F-4FB6-A2D8-2AB6ADF9C0B6Q34663619-E8179763-2CAF-4B7F-9936-912D3856B405Q34677690-71DA5F4A-1714-4E5E-A758-C2E49AB9CCC7Q34785423-ED6F75C9-FB8C-46B1-9147-5DB27E536562Q35022825-1ACC10A6-F398-41E2-B77F-5BC100C06A8DQ35168104-89DFF3F8-C0AC-4426-A5C5-25620C94155EQ35630889-6670148F-E75C-4416-AAEE-2507E0841A1BQ35682549-2DD1B9EC-2A41-4BDA-9743-8C9933FE91B0Q35928846-92547F20-CC44-444D-B3EB-CBD06DB6014FQ36153325-10AF9418-2DFB-4F76-9BFC-4AFE0E49319DQ36393206-96D0BD20-97DD-46D9-A706-5B13A51A7721Q36528089-498922D3-9B76-4AF7-90A2-E505DCC82749Q36924486-3E904165-9E44-42BB-BBBD-3C4B4AD54F8BQ36987053-47FE8827-DC39-4DB7-9954-DF032B1B83EEQ36990578-4180D157-BF47-4407-A9E7-EE082A559FBAQ37174025-203813DC-D3CB-475F-88C3-3837BEFF9D33
P50
description
onderzoeker
@nl
name
Rosette Lidereau
@ast
Rosette Lidereau
@en
Rosette Lidereau
@es
Rosette Lidereau
@nl
Rosette Lidereau
@sl
type
label
Rosette Lidereau
@ast
Rosette Lidereau
@en
Rosette Lidereau
@es
Rosette Lidereau
@nl
Rosette Lidereau
@sl
prefLabel
Rosette Lidereau
@ast
Rosette Lidereau
@en
Rosette Lidereau
@es
Rosette Lidereau
@nl
Rosette Lidereau
@sl